相关实验视频

Updated: Jul 15, 2025

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

在携带LRRK2 G2019S突变的患者中,快速进展的多个系统缩

Tommaso Carrer¹, Giulia Bonato¹, Michele Sandre¹

¹Parkinson and Movement Disorders Unit, Center for Rare Neurological Diseases (ERN-RND), Study Center On Neurodegeneration (CESNE), Department of Neuroscience, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

|September 26, 2023

概括

基因检测显示,G2019S LRRK2突变发生在患有快速进展的多系统性缩 (MSA) 的患者身上. 这表明LRRK2突变可能会增加MSA风险,因此在非典型帕金森症中需要进行遗传查.

科学领域:

神经科学是一个神经科学.
遗传学是一个遗传学.
神经学神经学

背景情况:

多系统缩 (MSA) 通常是零星的,对其遗传基础的理解有限.
遗传因素在MSA病因学中的作用在很大程度上仍未被探索.

研究的目的:

调查LRRK2突变与多系统性缩 (MSA) 之间的潜在遗传联系.
报告一种非典型的帕金森症病例,具有暗示MSA的特征,藏着已知的帕金森病相关突变.

主要方法:

一个患有快速进展的帕金森症,双自律症和圆柱状症状的患者的临床表现,诊断为MSA-P.
诊断工作包括DAT-SPECT,T2-MRI,FDG-PET和遗传检测.
皮肤活检用于α-synuclein RT-QuIC和免疫组织化学,以及测量神经丝光链水平.

主要成果:

患者的临床和放射性发现与MSA-P一致.
基因分析确定了LRRK2基因中的G2019S突变.
皮肤活检显示了异常的α-synuclein沉积物,支持MSA,尽管RT-QuIC是负的.

结论:

在帕金森病中常见的G2019S LRRK2突变在患有MSA特征的患者中被发现.
这一案例表明G2019S LRRK2突变与患MSA的风险增加之间存在潜在的关联.
对于非典型帕金森症,特别是在特定人群中,建议对与PD相关的基因进行查.

关键词:

G2019SS G2019SS G2019S G2019S G2019S G2019S G2019S G2019S G2019S G2019 这是LRRK2 在MSA中,MSA是MSA.美国人美国人

更多相关视频

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

Assaying the Kinase Activity of LRRK2 in vitro

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

相关概念视频

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Lysosomal Hydrolases

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...